Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:
“MATTERHORN Trial – ASCO 2025 Spotlight
Can perioperative immunotherapy change outcomes in resectable gastric/GEJ cancer?
At GI25, MATTERHORN (Durvalumab + FLOT) showed:
- pCR: 19% vs 7%
- T0: 23% vs 11%
- N0: 52% vs 36%
As Per press release: EFS is statistically significant and clinically meaningful.
But KN585 – PCR BENIFIT but no EFS gain
Why MATTERHORN may succeed where KEYNOTE-585 fell short:
- 100% got triplet chemo (vs 20% in KN585)
- 60% completed peri-op FLOT (vs 48 % )
Now your turn- put your brain and give me your best guess for the EFS outcome?
HR and Gain in median EFS.
More posts featuring Amol Akhade.